Compare Procter & Gamble Health with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs ASTRAZENECA PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA PROCTER & GAMBLE HEALTH/
ASTRAZENECA PHARMA
 
P/E (TTM) x 47.3 116.2 40.8% View Chart
P/BV x 5.1 34.0 14.9% View Chart
Dividend Yield % 9.4 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
ASTRAZENECA PHARMA
Mar-18
PROCTER & GAMBLE HEALTH/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5491,278 277.7%   
Low Rs1,301883 147.4%   
Sales per share (Unadj.) Rs511.4228.4 223.9%  
Earnings per share (Unadj.) Rs61.310.4 591.4%  
Cash flow per share (Unadj.) Rs74.016.3 455.2%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.898.8 939.3%  
Shares outstanding (eoy) m16.6025.00 66.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.7 100.3%   
Avg P/E ratio x39.6104.2 38.0%  
P/CF ratio (eoy) x32.866.4 49.3%  
Price / Book Value ratio x2.610.9 23.9%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,25727,008 149.1%   
No. of employees `0001.11.4 83.6%   
Total wages/salary Rs m1,3131,535 85.5%   
Avg. sales/employee Rs Th7,486.74,210.9 177.8%   
Avg. wages/employee Rs Th1,157.61,132.2 102.2%   
Avg. net profit/employee Rs Th897.2191.1 469.5%   
INCOME DATA
Net Sales Rs m8,4905,710 148.7%  
Other income Rs m244123 199.1%   
Total revenues Rs m8,7345,833 149.7%   
Gross profit Rs m1,482463 320.1%  
Depreciation Rs m211147 143.3%   
Interest Rs m00-   
Profit before tax Rs m1,514438 345.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m563179 314.4%   
Profit after tax Rs m1,017259 392.7%  
Gross profit margin %17.58.1 215.3%  
Effective tax rate %37.140.8 90.9%   
Net profit margin %12.04.5 264.1%  
BALANCE SHEET DATA
Current assets Rs m15,3433,209 478.1%   
Current liabilities Rs m1,9602,070 94.7%   
Net working cap to sales %157.620.0 789.8%  
Current ratio x7.81.6 504.8%  
Inventory Days Days4972 67.4%  
Debtors Days Days2835 81.5%  
Net fixed assets Rs m1,209790 153.0%   
Share capital Rs m16650 332.0%   
"Free" reserves Rs m15,2352,419 629.7%   
Net worth Rs m15,4012,469 623.7%   
Long term debt Rs m00-   
Total assets Rs m17,5954,605 382.0%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.2 38.9%   
Return on assets %5.85.6 102.8%  
Return on equity %6.610.5 63.0%  
Return on capital %10.317.7 57.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,636300 546.3%   
Fx outflow Rs m4,3682,015 216.8%   
Net fx Rs m-2,732-1,715 159.3%   
CASH FLOW
From Operations Rs m-1,30488 -1,483.3%  
From Investments Rs m12,697-94 -13,565.4%  
From Financial Activity Rs m-301NA-  
Net Cashflow Rs m11,093-6 -194,612.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 0.3 6,066.7%  
FIIs % 1.0 15.7 6.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 9.1 319.8%  
Shareholders   28,591 12,856 222.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Healthcare and Metal Stocks Witness Selling(Closing)

After staging a gap-down opening, Indian share markets recovered losses as the session progressed and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Aug 12, 2020 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS